Category - Developments

Developments

Imagin Medical reports upcoming 2020 milestones for i/Blue Imaging System

Imagin Medical (CSE:IME; OTCQB:IMEXF; Frankfurt & Stuttgart Symbol:DPD2) reported its 2019 i/Blue Imaging System development achievements and upcoming 2020 milestones. “2019 was a momentous year for the Company as...

January 23, 2020

Developments

Genprex gets fast track designation for lung cancer gene therapy

The FDA granted fast track designation for Genprex’s (NASDAQ:GNPX) Oncoprex immunogene therapy in combination with osimertinib for the treatment of non-small cell lung cancer (NSCLC) patients with epidermal growth...

January 21, 2020

Developments

Aldeyra enrolls first patient in Phase 3 allergic conjunctivitis trial

Aldeyra Therapeutics (NASDAQ:ALDX) enrolled the first patient in its Phase 3 INVIGORATE trial of topical ocular reproxalap for the treatment of allergic conjunctivitis. The trial will enroll some 120 patients to assess...

January 21, 2020

Developments

Tyme Technologies doses first patient in Phase 2 sarcoma trial

Tyme Technologies (NASDAQ:TYME) dosed the first patient in its HopES Phase 2 trial evaluating SM-88 for the treatment of high-risk sarcomas. SM-88, or racemetyrosine, is a modified tyrosine derivative designed to...

January 16, 2020

Developments

Kala Pharma completes enrollment in Phase 3 dry eye disease trial

Kala Pharmaceuticals (NASDAQ:KALA) completed enrollment in its STRIDE 3 Phase 3 clinical trial of EYSUVIS for the short-term treatment of dry eye disease. The trial’s inclusion/exclusion criteria have been modified from...

January 15, 2020

Developments

Novavax gets fast track designation for NanoFlu in older adults

The FDA granted fast track designation for Novavax’s (NASDAQ:NVAX) NanoFlu, a seasonal influenza vaccine candidate, in adults 65 years of age and older. “We believe that NanoFlu will offer an innovative improvement...

January 15, 2020

Developments

Mesoblast to complete rolling BLA for Ryoncil this month

Mesoblast (NASDAQ:MESO; ASX:MSB) plans to file the final module of the rolling biologics license application for Ryoncil with the FDA in January and then request a priority review of the BLA under the product...

January 15, 2020

Developments

IntelGenx gets Health Canada approval to proceed with amended Phase 2a Montelukast VersaFilm trial

Health Canada has issued a no objection letter in response to IntelGenx’s (TSXV:IGX; OTCQX:IGXT) amended clinical trial application for the ongoing Montelukast VersaFilm Phase 2a (BUENA) clinical trial in patients with...

January 15, 2020

Developments

Mereo BioPharma reports additional positive Phase 2b setrusumab data

Mereo BioPharma (NASDAQ:MREO) reported additional data from its Phase 2b ASTEROID clinical study of setrusumab in adults with Type 1, 3, and 4 osteogenesis imperfecta (OI). OI, also known as brittle bone disease, is...

January 14, 2020

Developments

BioLineRx gets EMA orphan drug designation for pancreatic cancer drug

BioLineRx (NASDAQ:BLRX) received European Medicines Agency orphan drug designation (ODD) for motixafortide for the treatment of pancreatic cancer. Motixafortide is a short synthetic peptide designed to target CXCR4, a...

January 14, 2020

Category - Developments

Imagin Medical reports upcoming 2020 milestones for i/Blue Imaging System

Genprex gets fast track designation for lung cancer gene therapy

Aldeyra enrolls first patient in Phase 3 allergic conjunctivitis trial

Tyme Technologies doses first patient in Phase 2 sarcoma trial

Kala Pharma completes enrollment in Phase 3 dry eye disease trial

Novavax gets fast track designation for NanoFlu in older adults

Mesoblast to complete rolling BLA for Ryoncil this month

IntelGenx gets Health Canada approval to proceed with amended Phase 2a Montelukast VersaFilm trial

Mereo BioPharma reports additional positive Phase 2b setrusumab data

BioLineRx gets EMA orphan drug designation for pancreatic cancer drug

Follow Us

General

More

Subscribe